Chinese scientists have developed "three anti-one repair" interstuming stem cells

4, reporters from the Army Medical University Army Speciality Medical Center was informed that the center researchers have developed a "three anti-one repair" interstumin stem cells with antibacterial, anti-toxic, anti-inflammatory and tissue repair capabilities. At present, the cell has completed animal experiments. In the future, this new type of interstume stem cells is expected to become the killer of sepsis. The results were published in the American Journal of Molecular Therapy.
sepsis is an over-inflammatory response syndrome caused by bacterial or viral infections, which is the main cause of late-stage death in patients with critical emergency medical infection, and there is no effective treatment. When patients with sepsis are treated with high doses of antibiotics, antibiotics kill pathogens while the dead pathogens release excessive amounts of toxins and bacterial DNA, which can further stimulate the body's excessive inflammatory response, leading to multi-organ dysfunction and accelerate the patient's death.
" how to balance toxins at the same time as sterilization has become an important scientific issue in the treatment of sepsis. Xu Xiang, director of the Stem Cell and Regenerative Medicine Department at the Army Medical University's Army Specialty Medical Center, said that in past studies, a single treatment measure against a key medium or regulatory link in the pathogenesis of sepsis has not achieved satisfactory clinical results.
, the researchers designed interstumined stem cells with antibacterial, anti-toxic, anti-inflammatory and tissue repair capabilities. In the treatment of sepsis model mice, the new interstitial stem cells can significantly reduce the bacterial load and serum inflammatory factors of the main organs, and significantly improve the ability to remove endotoxins in the serum, tissue repair ability and survival rate of mice, especially the survival rate of drug-resistant Staphylococcus aphdote infection increased from 20.7% to 56.7%.
Xu Xiang said that the research team will further develop a new type of interstumined stem cell transplantation to treat sepsis clinical transformation research work, if the effective application of this strategy, will greatly improve the clinical treatment effect of sepsis, or can rewrite the phenomenon of multiple drug resistance, drug-free control.